Global Ophthalmic Anti-VEGF Therapeutics Market Size Is Poised To Reach USD 28.5 Billion By 2035 | CAGR of 5.09%

Global Ophthalmic Anti-VEGF Therapeutics Market Size Is Poised To Reach USD 28.5 Billion By 2035

According to a research report published by Spherical Insights & Consulting, the Global Ophthalmic Anti-VEGF Therapeutics Market is expected to grow from USD 16.5 Billion in 2024 to USD 28.5 Billion by 2035, at a CAGR of 5.09% during the forecast period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global Ophthalmic Anti-VEGF Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Biologics and Biosimilars), By Indication (Age-related macular degeneration, Diabetic retinopathy, Macular edema, Retinal vein occlusion, and Myopic choroidal neovascularization), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.  https://www.sphericalinsights.com/reports/ophthalmic-anti-vegf-therapeutics-market

The ophthalmic anti-VEGF therapeutics market refers to the worldwide industry encompassing drugs that are designed for blocking vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage that cause vision loss in diseases like neovascular AMD and diabetic macular edema. Anti-VEGF medications minimize leaky aberrant blood vessels in the retina by blocking VEGF, which reduces or eliminates the damage caused by the aberrant blood vessels and slows down the loss of eyesight. An increasing prevalence of eye diseases and ageing population, along with technological advancements in drug development, are driving the ophthalmic anti-VEGF therapeutics market. Further, the awareness towards timely treatment of ophthalmic disorders is propelling the market growth. However, increased treatment cost, as well as side effects and safety concerns associated with anti-VEGF therapeutics, are challenging the market.

The biologics segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR of about 4.8% during the forecast period.

Based on the drug type, the ophthalmic anti-VEGF therapeutics market is divided into biologics and biosimilars. Among these, the biologics segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR of about 4.8% during the forecast period. Biologics against VEGF are important for treating many retinal diseases, typically imposing a high financial burden. Further, its strong clinical outcomes and established usage in wet AMD, DME, and DR support are propelling the segmental market growth.

The age-related macular degeneration segment accounted for the largest share of around 47.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the indication, the ophthalmic anti-VEGF therapeutics market is divided into age-related macular degeneration, diabetic retinopathy, macular edema, retinal vein occlusion, and myopic choroidal neovascularization. Among these, the age-related macular degeneration segment accounted for the largest share of around 47.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The prevalence of AMD is expected to increase from 170 million to 288 million by the year 2040. An increasing ageing population is contributing to drive the segmental market.

North America is expected to hold the majority share of the global ophthalmic anti-VEGF therapeutics market during the forecast period.

North America is expected to hold the majority share of 64.2% in the global ophthalmic anti-VEGF therapeutics market during the forecast period. The United States is the dominant country in the North America ophthalmic anti-VEGF therapeutics market, owing to the growing disease prevalence and approval & commercialization of new products. North America has a robust market ecosystem that includes the region’s well-established retina specialty centres, ambulatory surgical centres, and ophthalmology clinics.     

Asia Pacific is anticipated to grow at the fastest pace of about 7.0% CAGR in the global ophthalmic anti-VEGF therapeutics market during the forecast period. Japan is the leading country in the Asia Pacific market, holding the dominant share of over 27.8%, owing to an increased ageing population. In the Asia Pacific Ophthalmic Anti-VEGF Therapeutics market, factors like sedentary lifestyles, high-calorie diets, and increased obesity that are responsible for the increased prevalence of retinal vascular disorders are contributing to propel the market.  

Major vendors in the global ophthalmic anti-VEGF therapeutics market are AMGEN, Astellas, Biocon Biologics, Biogen, CELLTRION, Intas Pharmaceuticals, KANGHONG PHARMACEUTICALS, LUPIN, NOVARTIS, REGENERON, Reliance Life Sciences, Roche, SANDOZ, STADA, and teva, and Others.   

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In September 2025, Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company, announced its launch with an initial $100 million in financing led by ARCH Venture Partners, Mubadala Capital and Monograph Capital.

• In July 2025, Harrow, a leading North American eyecare pharmaceutical company, announced that it had entered into a definitive agreement with Samsung Bioepis Co. Ltd. to secure the exclusive US commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis, BYOOVIZ (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS (ranibizumab), and OPUVIZ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept), two of the most widely used anti-VEGF therapies for retinal diseases.  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Ophthalmic Anti-VEGF Therapeutics market based on the below-mentioned segments:

Global Ophthalmic Anti-VEGF Therapeutics Market, By Drug Type

• Biologics
• Biosimilars

Global Ophthalmic Anti-VEGF Therapeutics Market, By Indication

• Age-related macular degeneration
• Diabetic retinopathy
• Macular edema
• Retinal vein occlusion
• Myopic choroidal neovascularization

 Global Ophthalmic Anti-VEGF Therapeutics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa